
<p>
    Listing and Waitlist Management (HCC):
</p>
<p>
    Review LIVa-006.SD01 for full details on the clinical, regulatory, and institutional standards for evaluating HCC patients for liver transplant candidacy at the Ajmera Transplant Centre.
</p>
<ul>
    <li data-list-item-id="ecb1f3b72dbff894c93f2b5469ab1798e">
        All referrals for HCC must follow the <strong>Liver Transplant Referral Process (LIVa-001).</strong>
    </li>
    <li data-list-item-id="e7780e9358c333c37d038b6cac272392f">
        <strong>Within TGLN criteria:</strong> Patients seen by a transplant hepatologist within 2 weeks.
    </li>
    <li data-list-item-id="e68f5c4669a4fb7d6c82a92cf08dc05a6">
        <strong>Outside TGLN criteria:</strong> Redirected to <strong>Surgical Oncology</strong>, with potential re-referral at their discretion.
    </li>
    <li data-list-item-id="e4191f7e6eb4223efb8d27b4c0f62a606">
        Surgical oncology is responsible for imaging, bridging therapy, and presenting at HCC/HPB rounds.
    </li>
    <li data-list-item-id="ec8023d1edb33edcbf05d0342c8d5ad0d">
        Decisions are documented in EPIC.
    </li>
</ul>
<p>
    <strong>Eligibility Criteria:</strong>
</p>
<ul>
    <li data-list-item-id="e0f61668cd4b7235ff68242d7a086d66d">
        Meet minimum eligibility as outlined in SOP LIVa-002 and LIVa-003
    </li>
    <li data-list-item-id="e4328276961565906f03d59ea6273f028">
        The disease trajectory must justify transplant compared to expected survival post-transplant
    </li>
    <li data-list-item-id="e992c80ff4c3954346ba35d9a6b595fb3">
        All alternative treatments must be considered prior to referral.
    </li>
    <li class="ck-list-marker-bold" data-list-item-id="eaf06def369d7c3668a27913ca29cb64f">
        <strong>Deceased Donor (Ontario Criteria):</strong>
        <ul>
            <li data-list-item-id="ed21130e77aa25c8e97dc1d5256d8038e">
                Total Tumor Volume (TTV) ≤ 145 cm³ and AFP &lt; 1000 ng/mL (TTV = 4/3 πr³)
            </li>
            <li data-list-item-id="e4a9387b8acf3e9e3ce13a02d294472d9">
                Single tumors &lt;2 cm successfully treated with ablation/resection are <strong>not eligible</strong> for exception points.
            </li>
            <li data-list-item-id="ef0dedee3b5621a972dab63ccc6716df3">
                Recurrent HCC within criteria may be eligible for exception points if recurrence occurs within 5 years.
            </li>
        </ul>
    </li>
    <li class="ck-list-marker-bold" data-list-item-id="e4a57804baa08aed0178989653eee72a1">
        <strong>Living Donor (Extended Toronto Criteria):</strong>
        <ul>
            <li data-list-item-id="e891f5a3faa8605ae91808530363b39b6">
                TTV &gt; 145 cm³ allowed if AFP &lt; 1000 ng/mL, <strong>and </strong>No cancer symptoms/No extrahepatic disease or vascular invasion/No poor tumor differentiation on biopsy
            </li>
            <li data-list-item-id="e0d66aea85d957c460ba6d0b7e0a980d7">
                If AFP &gt; 1000 ng/mL, downstaging via locoregional therapy is required.
            </li>
        </ul>
    </li>
</ul>
<img class="img-fluid mx-auto d-block" src="pages/images/03_01_01.png"/>
<p>
    <strong>Contraindications (Pre-Transplant):</strong>
</p>
<ul>
    <li data-list-item-id="e68c3b6b45d5ffbdf5db0f92b33629cc1">
        Absolute
        <ul>
            <li data-list-item-id="ee2036cb9f9e434c2fe7ffed09daeaeee">
                Any contraindication in SOP LIVa-002
            </li>
            <li data-list-item-id="e10b48a0e6315f3232ddd566445e207ca">
                Extrahepatic spread or vascular invasion <strong>unless part of a research protocol</strong>
            </li>
            <li data-list-item-id="ef93ed271bb099ca01f0987dd7224bffa">
                Mixed HCC/cholangiocarcinoma histology
            </li>
        </ul>
    </li>
    <li data-list-item-id="ecee0d8ff25eaacea9746a9b3ec3366ee">
        Relative
        <ul>
            <li data-list-item-id="e329c0785c2c6998b5cdc1cc1958b7e57">
                Case-by-case review by transplant team if any relative contraindications are present (see SOP LIVa-002)
            </li>
        </ul>
    </li>
</ul>
<p>
    <strong>Waitlist Monitoring:</strong>
</p>
<p>
    All listed HCC candidates will undergo regular surveillance to ensure continued eligibility including:
</p>
<ul>
    <li data-list-item-id="e69185e01b7d1496380f9917d794dffd7">
        CT chest/abdomen/pelvis every 3 months
    </li>
    <li data-list-item-id="e4a175cd3c3237e17f64a93c455910333">
        AFP measurement every 3 months
    </li>
    <li data-list-item-id="ef6cc57c706344fce31bd6513bedf8fb3">
        Bridging therapies documented and organized by surgical oncology
    </li>
    <li data-list-item-id="e6211da4b9f9ceb0dae420375104b9e85">
        Exception points may be granted during monitoring
    </li>
</ul>
<p>
    <strong>Immune Checkpoint Inhibitor (ICI) Considerations</strong>
</p>
<ul>
    <li data-list-item-id="e54184813a75111e4b160dcddbdb2de72">
        All <strong>HCC patients beyond Milan criteria</strong> should be considered for ICI-based therapy.
    </li>
    <li data-list-item-id="e856d166a6adfe30f61b518358800cf8f">
        Patients on ICI will be <strong>placed on hold</strong> once MELD reaches 30 exception points.
    </li>
    <li data-list-item-id="ef0d6e7651566dec266ce7a1fae888f91">
        ICI is <strong>discontinued at MELD 30</strong>, and patients are <strong>re-activated after a 6-week washout</strong> period.
    </li>
    <li data-list-item-id="e4727d814ec2f2daf445e7f04b9927556">
        Bridging options discussed at HCC/HPB rounds
    </li>
    <li data-list-item-id="e068c56a1f05b8b4e1f7f8852e40e6c2b">
        Review ICI Section
    </li>
</ul>
<p>
    Review: Liver Transplantation for HCC at UHN SOP
</p>